

Patient Sample	Chromosomal Abnormality	% Clonal Cells in Marrow#	Age	Gender	Disease Status	Hct	Plt	WBC	Mono	% Marrow Cellularity	IPSS	% Blasts	% Purity of CD14 Cells [§]	MMP9 Gene Expression			Prior Treatment *
														Time 0	Day 5 in	Day 5 in	
1			73	f	RA	37	27	3.37	0.44	98	N/A	4.0	93	0.07	2.02	2.13	Epo
2			52	m	RA	38	51	2.19	0.11	98	1.5	5.0	74	0.00	4.45	4.32	no treatment
3	del 20q	55	77	m	RA	39	44	4.73	0.66	70	0.5	2.0	87	0.15	1.37	5.18	Amifostine, Trisenox/Neumega
4	t(2:11), del 5p+Xq	100	43	f	RA	36	321	2.82	0.28	90	1	2.0	88	0.07	2.98	6.84	Epo/G-CSF
5	del 20q	75	57	m	RA	34	41	2.77	0.22	100	1	3.0	87	0.08	3.93	7.23	no treatment
6	inv 16	45	52	m	RA	35	15	1.59	0.08	98	N/A	4.0	77	0.00	8.54	9.25	no treatment
7	t(1:7), del 7p	65	49	m	RA	39	132	2.45	0.12	90	1.5	1.0	84	0.37	3.84	11.66	no treatment
8	t(1:7), del 7	17	50	f	RA	35	171	5.26	0.53	20	1	0.9	82	0.07	5.80	14.10	no treatment
9			66	m	RA	27	101	6.62	0.79	70	1	N/A	94	0.15	3.25	14.27	Darbo
10	tri 15	18	45	f	RA	36	76	7.37	0.74	40	1	0.0	77	0.10	4.91	15.61	no treatment
11			52	m	RA	26	193	1.73	0.05	80	2	4.5	81	2.77	8.45	17.51	no treatment
12	del 12	85	65	m	RAEB	34	27	5.07	0.71	95	1.5	N/A	86	0.05	6.40	3.15	no treatment
13	tri 8	95	24	m	RAEB	29	714	2.23	0.07	98	N/A	8.5	63	0.00	4.19	7.02	no treatment
14			45	f	RAEB	24	122	2.40	N/A	100	1	7.0	90	0.40	6.75	9.31	Darbo
15			47	m	RAEB	39	85	3.19	0.10	60	1.5	10.0	68	0.38	N/A	9.67	no treatment
16	del Y	N/A	61	m	RAEB	26	38	1.02	0.04	30	2	13.0	71	0.88	15.61	10.88	no treatment
17	del20q, t(13:14)	85%	38	m	RAEB	31	29	1.17	0.09	60	1.5	10.0	82	0.11	2.63	11.41	no treatment
18			61	f	RAEB	31	49	5.34	0.43	70	2.5	3.0	84	0.38	22.49	14.01	Topotecan/AraC
19			49	f	RAEB	30	28	4.60	0.18	40	1	10.0	83	1.60	8.92	14.54	Thalidomide/Darbo
20			57	f	RAEB	29	79	1.15	0.02	20	1	6.0	73	0.35	8.40	19.30	no treatment
21	t(11:19)	N/A	48	f	RAEB	28	29	2.70	0.02	30	2	18.0	74	0.27	1.13	25.03	Prednisone, Epo
22			50	m	RARS	29	111	1.42	0.28	65	0.5	3.0	89	0.01	13.45	4.00	G-CSF
23			58	m	CMML	39	106	4.68	2.34	80	N/A	0.6	93	0.06	2.45	12.00	no treatment
24			67	m	unclassified	26	101	7.34	0.88	70	N/A	5.0	82	0.00	6.46	6.02	Darbo
25	del 20q	100	56	f	unclassified	44	222	17.57	0.70	65	1.5	N/A	84	0.21	3.51	6.45	no treatment
26			58	m	unclassified	39	213	6.57	0.20	90	0.5	N/A	91	0.11	3.19	6.88	Epo/Thalidomine, 5-AzaC
27			29	m	unclassified	24	239	3.27	0.23	65	1.5	2.4	82	0.02	4.04	21.35	Prednisone, lenalidomide, CSA/ATG

Percentage of clonal cells in marrow was determined by karyotype analysis in cultured marrow cells. The analysis was conducted by the FHCRC cytogenetics laboratories.

§ Percentage of purity of CD14 cells was determined by Flow cytometry.

* All blood samples were obtained prior to the transplant conditioning regimen.

Abbreviations: 5-AzaC, 5-azacytidine; AraC, cytarabine; ATG, anti-thymocyte globulin; Darbo, darbopoeitin; CSA, cyclosporine-A; Epo, erythropoietin; G-CSF, granulocyte colony-stimulating factor; N/A stands for data not available.